April 23 | 2021

Teckningskursen för utnyttjande av teckningsoptioner av serie TO1 i 2cureX AB har fastställts till 13,22 SEK och teckningsperioden inleds den 26 april 2021

Read more
April 23 | 2021

The exercise price for the warrants of series TO1 in 2cureX AB has been determined to SEK 13.22 and the subscription period starts April 26, 2021

Read more
March 1 | 2021

2cureX announces that the clinical trial of IndiTreat®-guided treatment of metastatic colorectal cancer has met the primary endpoint.

Read more
February 25 | 2021

2cureX offentliggör bokslutskommuniké för räkenskapsåret 2020.

Read more
February 25 | 2021

2cureX publishes year-end report for 2020.

Read more
February 4 | 2021

IndiTreat® selected to prestigious multinational ovarian cancer project.

Read more
January 28 | 2021

2cureX appoints Kenneth Graabek Johansen, an experienced business and financial executive, as new CFO.

Read more
January 21 | 2021

Last patient treated in the world’s first interventional trial with 3D microtumors as guide for choice of cancer treatment.

Read more
January 5 | 2021

2cureX appoints Fernando Andreu, an international Biotech executive, as new CEO

Read more
December 23 | 2020

Key achievements in 2020 – an IndiTreat ® Launch year

Read more
November 26 | 2020

2cureX offentliggör delårsrapport för det tredje kvartalet 2020.

Read more
November 26 | 2020

2cureX publishes interim report for the third quarter of 2020.

Read more
November 26 | 2020

2cureX launches new website

Read more
November 11 | 2020

2cureX presents commercial roadmap 2021 – 2023

Read more
November 11 | 2020

2cureX presents commercial roadmap 2021 – 2023

Read more
November 5 | 2020

Announcement from 2cureX extra general meeting

Read more
November 5 | 2020

Kommuniké från extra bolagsstämma i 2cureX

Read more